Use of psylocybin in the treatment of psychiatric disorders: Literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/44971 |
Resumo: | Objective: To describe the information available in the literature regarding the use of psilocybin in the treatment of psychiatric disorders, its mechanisms of action and toxicity, as well as other relevant data on the subject. Methodology: This paper presents a narrative review of the literature, which allows for the synthesis of multiple studies, thus enabling general conclusions about a particular subject. The searches took place between the months of September and December of 2023, in the following databases: PubMed, Virtual Health Library, SciELO and Google Scholar. The critical analysis of the studies and the synthesis of bibliographic data were performed descriptively, grouped in topics relevant to the studied subject. Results: Given its mechanism of action – psilocybin acts mainly as an agonist of the 5-receptorHT2A, acting in the serotonergic system, amplifying the action of serotonin in the synaptic cleft and promoting qualitative and quantitative changes in brain function –, several studies relate psilocybin to the improvement of symptoms of depression and anxiety. As for the evaluation of the toxicity of this substance, psilocybin is generally considered of low-toxicity, not generating physical dependence. Conclusion: Considering the above, there is potential for this hallucinogen in the treatment of psychiatric disorders, such as depression and anxiety. However, more studies are still needed to better understand the efficacy of psilocybin, its risks and benefits, as well as to verify regulatory aspects and protocols for its safe and rational use. |
id |
UNIFEI_85c0de9f99f794fa0b44c1a8d61f79ac |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/44971 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Use of psylocybin in the treatment of psychiatric disorders: Literature reviewUso de psilocibina en el tratamiento de trastornos psiquiátricos: Revisión de la literaturaUso da psilocibina no tratamento de transtornos psiquiátricos: Revisão da literaturaTrastornos mentalesPsilocibinaAlucinógenosPsiquiatría. Mental disordersPsilocybinHallucinogensPsychiatry.Transtornos mentaisPsilocibinaAlucinógenosPsiquiatria.Objective: To describe the information available in the literature regarding the use of psilocybin in the treatment of psychiatric disorders, its mechanisms of action and toxicity, as well as other relevant data on the subject. Methodology: This paper presents a narrative review of the literature, which allows for the synthesis of multiple studies, thus enabling general conclusions about a particular subject. The searches took place between the months of September and December of 2023, in the following databases: PubMed, Virtual Health Library, SciELO and Google Scholar. The critical analysis of the studies and the synthesis of bibliographic data were performed descriptively, grouped in topics relevant to the studied subject. Results: Given its mechanism of action – psilocybin acts mainly as an agonist of the 5-receptorHT2A, acting in the serotonergic system, amplifying the action of serotonin in the synaptic cleft and promoting qualitative and quantitative changes in brain function –, several studies relate psilocybin to the improvement of symptoms of depression and anxiety. As for the evaluation of the toxicity of this substance, psilocybin is generally considered of low-toxicity, not generating physical dependence. Conclusion: Considering the above, there is potential for this hallucinogen in the treatment of psychiatric disorders, such as depression and anxiety. However, more studies are still needed to better understand the efficacy of psilocybin, its risks and benefits, as well as to verify regulatory aspects and protocols for its safe and rational use.Objetivo: Describir las informaciones disponibles en la literatura acerca del uso de la psilocibina en el tratamiento de los trastornos psiquiátricos, mecanismos de acción y de toxicidad, entre otras informaciones relevantes sobre la temática. Metodología: Se trata de una revisión de literatura narrativa, que permite la síntesis de múltiples estudios publicados y posibilita conclusiones generales acerca de un determinado objeto. Las búsquedas ocurrieron entre los meses de septiembre y diciembre de 2023, en las bases de datos: PubMed, Biblioteca Virtual en Salud, SciELO y Google Académico. El análisis crítico de los estudios y la síntesis de los datos bibliográficos fueron realizados de forma descriptiva, agrupados por temas pertinentes al tema estudiado. Resultados: En la literatura se observan estudios que relacionan psilocibina con la mejora de los síntomas de la depresión y ansiedad, teniendo en cuenta su mecanismo de acción, pues la psilocibina actuará principalmente como agonista del receptor 5-HT2A, actuando en el sistema serotoninérgico amplificando la acción de la serotonina en la hendidura sináptica y promoviendo alteraciones cualitativas y cuantitativas del funcionamiento cerebral. En cuanto a la evaluación de la toxicidad de esta sustancia, la psilocibina se considera generalmente de baja toxicidad, no genera dependencia física. Conclusión: Ante lo expuesto, se verifica un potencial de ese alucinógeno para el tratamiento de trastornos psiquiátricos, como depresión y ansiedad. Sin embargo, aún son necesarios más estudios para entender mejor la eficacia de la psilocibina, sus riesgos y beneficios, así como verificar aspectos regulatorios y protocolos para su uso seguro y racional.Objetivo: Descrever as informações disponíveis na literatura acerca do uso da psilocibina no tratamento de transtornos psiquiátricos, seus mecanismos de ação e toxicidade, dentre outras informações relevantes sobre a temática. Metodologia: Trata-se de uma revisão de literatura narrativa, que permite a síntese de múltiplos estudos publicados e possibilita conclusões gerais acerca de um determinado assunto. As buscas ocorreram entre os meses de setembro e dezembro de 2023, nas bases de dados: PubMed, Biblioteca Virtual em Saúde, SciELO e Google Acadêmico. A análise crítica dos estudos e a síntese dos dados bibliográficos foram realizadas de forma descritiva, agrupados por tópicos pertinentes ao assunto estudado. Resultados: Na literatura observam-se estudos que relacionam psilocibina a melhora dos sintomas de depressão e ansiedade, tendo em vista seu mecanismo de ação, pois a psilocibina atua principalmente como agonista do receptor 5-HT2A, agindo no sistema serotonérgico amplificando a ação da serotonina na fenda sináptica e promovendo alterações qualitativas e quantitativas do funcionamento cerebral. Quanto à avaliação da toxicidade dessa substância, a psilocibina é geralmente considerada de baixa toxicidade, não gerando dependência física. Conclusão: Ante o exposto, verifica-se um potencial desse alucinógeno para o tratamento de transtornos psiquiátricos, como depressão e ansiedade. Porém, ainda são necessários mais estudos para melhor entender a eficácia da psilocibina, seus riscos e benefícios, bem como verificar aspectos regulatórios e protocolos para seu uso seguro e racional.Research, Society and Development2024-02-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4497110.33448/rsd-v13i2.44971Research, Society and Development; Vol. 13 No. 2; e2813244971Research, Society and Development; Vol. 13 Núm. 2; e2813244971Research, Society and Development; v. 13 n. 2; e28132449712525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/44971/35907Copyright (c) 2024 Gabriella Brandão Teixeira; Ana Cláudia de Brito Passos; Beatriz Valentim Farias; Ana Beatriz Cavalcanti Fernandes Girão ; Larissa da Silva Marçal; Ketsya Oliveira dos Santos Albuquerque; Maria Augusta Drago Ferreirahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessTeixeira, Gabriella Brandão Passos, Ana Cláudia de Brito Farias, Beatriz Valentim Girão , Ana Beatriz Cavalcanti Fernandes Marçal, Larissa da Silva Albuquerque, Ketsya Oliveira dos Santos Ferreira, Maria Augusta Drago 2024-03-04T09:47:20Zoai:ojs.pkp.sfu.ca:article/44971Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-03-04T09:47:20Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Use of psylocybin in the treatment of psychiatric disorders: Literature review Uso de psilocibina en el tratamiento de trastornos psiquiátricos: Revisión de la literatura Uso da psilocibina no tratamento de transtornos psiquiátricos: Revisão da literatura |
title |
Use of psylocybin in the treatment of psychiatric disorders: Literature review |
spellingShingle |
Use of psylocybin in the treatment of psychiatric disorders: Literature review Teixeira, Gabriella Brandão Trastornos mentales Psilocibina Alucinógenos Psiquiatría. Mental disorders Psilocybin Hallucinogens Psychiatry. Transtornos mentais Psilocibina Alucinógenos Psiquiatria. |
title_short |
Use of psylocybin in the treatment of psychiatric disorders: Literature review |
title_full |
Use of psylocybin in the treatment of psychiatric disorders: Literature review |
title_fullStr |
Use of psylocybin in the treatment of psychiatric disorders: Literature review |
title_full_unstemmed |
Use of psylocybin in the treatment of psychiatric disorders: Literature review |
title_sort |
Use of psylocybin in the treatment of psychiatric disorders: Literature review |
author |
Teixeira, Gabriella Brandão |
author_facet |
Teixeira, Gabriella Brandão Passos, Ana Cláudia de Brito Farias, Beatriz Valentim Girão , Ana Beatriz Cavalcanti Fernandes Marçal, Larissa da Silva Albuquerque, Ketsya Oliveira dos Santos Ferreira, Maria Augusta Drago |
author_role |
author |
author2 |
Passos, Ana Cláudia de Brito Farias, Beatriz Valentim Girão , Ana Beatriz Cavalcanti Fernandes Marçal, Larissa da Silva Albuquerque, Ketsya Oliveira dos Santos Ferreira, Maria Augusta Drago |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Teixeira, Gabriella Brandão Passos, Ana Cláudia de Brito Farias, Beatriz Valentim Girão , Ana Beatriz Cavalcanti Fernandes Marçal, Larissa da Silva Albuquerque, Ketsya Oliveira dos Santos Ferreira, Maria Augusta Drago |
dc.subject.por.fl_str_mv |
Trastornos mentales Psilocibina Alucinógenos Psiquiatría. Mental disorders Psilocybin Hallucinogens Psychiatry. Transtornos mentais Psilocibina Alucinógenos Psiquiatria. |
topic |
Trastornos mentales Psilocibina Alucinógenos Psiquiatría. Mental disorders Psilocybin Hallucinogens Psychiatry. Transtornos mentais Psilocibina Alucinógenos Psiquiatria. |
description |
Objective: To describe the information available in the literature regarding the use of psilocybin in the treatment of psychiatric disorders, its mechanisms of action and toxicity, as well as other relevant data on the subject. Methodology: This paper presents a narrative review of the literature, which allows for the synthesis of multiple studies, thus enabling general conclusions about a particular subject. The searches took place between the months of September and December of 2023, in the following databases: PubMed, Virtual Health Library, SciELO and Google Scholar. The critical analysis of the studies and the synthesis of bibliographic data were performed descriptively, grouped in topics relevant to the studied subject. Results: Given its mechanism of action – psilocybin acts mainly as an agonist of the 5-receptorHT2A, acting in the serotonergic system, amplifying the action of serotonin in the synaptic cleft and promoting qualitative and quantitative changes in brain function –, several studies relate psilocybin to the improvement of symptoms of depression and anxiety. As for the evaluation of the toxicity of this substance, psilocybin is generally considered of low-toxicity, not generating physical dependence. Conclusion: Considering the above, there is potential for this hallucinogen in the treatment of psychiatric disorders, such as depression and anxiety. However, more studies are still needed to better understand the efficacy of psilocybin, its risks and benefits, as well as to verify regulatory aspects and protocols for its safe and rational use. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-02-09 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/44971 10.33448/rsd-v13i2.44971 |
url |
https://rsdjournal.org/index.php/rsd/article/view/44971 |
identifier_str_mv |
10.33448/rsd-v13i2.44971 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/44971/35907 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 13 No. 2; e2813244971 Research, Society and Development; Vol. 13 Núm. 2; e2813244971 Research, Society and Development; v. 13 n. 2; e2813244971 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052637584031744 |